drugset
drugset / Trial / NCT03877510

Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations

NCT03877510 ↗

Phase 3 Completed 419 enrolled Impax Laboratories, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.

Timeline

Start
2019-04-03
Primary completion
2022-03-21
Completion
2022-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject IPX203 Unknown — Oral

Indications

Parkinson disease